The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | 131I-apamistamab-led induction/conditioning prior to alloSCT in R/R AML: insights from SIERRA
Mark Litzow, MD, Mayo Clinic, Rochester, MN, presents findings from the Phase III SIERRA trial (NCT02665065), evaluating targeted radiation with 131I-apamistamab prior to non-myeloablative allogeneic stem cell transplantation (alloSCT), versus conventional chemotherapy, in patients ≥55 years old with relapsed/refractory (R/R) acute myeloid leukemia (AML). High liver doses of this treatment regimen (≥22 Gy) yielded durable complete remission (CR) rates, establishing 131I-apamistamab followed by alloSCT as a new standard of care. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Amgen: Research Funding, Consultancy; Astellas: Research Funding; Novartis: Research Funding; Syndax: Research Funding; Jazz: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Actinium: Research Funding; Pluristem: Research Funding; Biosight: Consultancy, Other: Data Monitoring Board; Abbvie: Research Funding; Beigene: Consultancy.
